Key result
Overall cumulative survival at 3 years was 51% for the Edwards SAPIEN valve versus 60% for the Medtronic CoreValve (P=0.021), though survival was similar in transfemorally treated patients.
Why the study?
Does the Edwards SAPIEN valve compared to the Medtronic CoreValve affect 3-year survival in patients undergoing TAVI who are not candidates for surgery?
Population
861 patients who were not candidates for surgical aortic valve replacement undergoing transcatheter aortic…
Comparison
Edwards SAPIEN transcatheter heart valve (n=460) vs Medtronic CoreValve transcatheter heart valve
Design
Cohort
Follow-up
3 years
Authors
Loading...
Similar survival after transfemoral TAVI with either valve; leaves open differential effects by access route in high-risk patients.
Cohort (n=861)
Yes
Does the Edwards SAPIEN valve compared to the Medtronic CoreValve affect 3-year survival in patients undergoing TAVI who are not candidates for surgery?
Absolute Event Rate: 51% vs 60%
p-value: p=0.021
In a real-world registry of patients refused for surgery, midterm 3-year survival after transfemoral TAVI was similar between the Edwards SAPIEN and Medtronic CoreValve systems when stratified by baseline risk.
Collas et al. (2015) conducted a cohort in Aortic valve disease requiring TAVI (n=861). Edwards SAPIEN transcatheter heart valve vs. Medtronic CoreValve transcatheter heart valve was evaluated on Overall cumulative survival at 3 years (p=0.021). Overall cumulative survival at 3 years was 51% for the Edwards SAPIEN valve versus 60% for the Medtronic CoreValve (P=0.021), though survival was similar in transfemorally treated patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: